Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion

摘要: Abstract Background Anti-epidermal growth factor receptor treatment strategies, i.e. monoclonal antibodies such as cetuximab and panitumumab, or epidermal (EGFR) small molecule tyrosine kinase inhibitors, erlotinib gefitinib, have expanded the options for different tumor types. Dermatologic toxic effects are most common side-effects of EGFR inhibitor therapy. They can profoundly affect patient's quality life. Purpose The aim this study was to provide interdisciplinary expert recommendations on how treat patients with skin reactions undergoing anti-EGFR treatment. Material methods An panel from Germany expertise in medical oncology, dermatology clinical pharmacology convened develop based published peer-reviewed literature. Results state-of-the-art induced by therapy include diagnostics grading well grade-specific stage-adapted approaches preventive measures. It concluded that EGFR-inhibitor-related dermatologic should always be treated combining basic care a specific adapted stage grade reaction. For 2 above, early- later-stage EGFR-inhibitor were proposed. Conclusion This paper presents German national opinion receiving